UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

November 1214, 2025

Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS INC /NV/

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-15697	22-3542636
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

(201) 750-2646

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ELTP		OTCQB

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On November 1214, 2025, ~~in a press release,~~ Elite Pharmaceuticals, Inc., or (“Elite,” ~~reported~~or ~~that~~the it“Company”) ~~received~~filed ~~approval~~its ~~from~~quarterly ~~the~~report USon ~~Food and~~Form ~~Drug~~10-Q ~~Administration (FDA)~~ for athe ~~generic~~quarter ~~version~~ended ofSeptember ~~Requip XL® (Ropinirole Extended-Release Tablets USP)~~30, ~~with~~2025 ~~strengths~~ of 2fiscal ~~mg, 4~~year mg2026, ~~6 mg~~and, ~~8 mg~~thereafter, ~~and~~issued 12a mgpress ~~tablets.~~release ~~Ropinirole~~announcing ~~belongs~~its tofinancial aresults for ~~class~~that ofquarter. ~~drugs~~A ~~known~~copy asof athe ~~non-ergoline~~press ~~dopamine~~release ~~agonist~~is ~~used~~furnished toas ~~treat~~Exhibit ~~symptoms of Parkinson’s disease~~99.1 ~~This~~hereto ~~product will be marketed~~ and ~~sold~~is ~~under~~incorporated ~~the~~herein ~~Elite~~by ~~Laboratories, Inc~~reference. ~~label.~~

AAs ~~copy~~noted ofin the press release, ~~is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in~~ the ~~press~~Company ~~release~~will ~~furnished~~host asa ~~Exhibit~~conference ~~99.1~~call ~~shall~~at ~~not~~11:30 beAM ~~deemed~~Eastern ~~“filed”~~Standard ~~for~~Time ~~purposes~~(EST) ofon ~~Section 18 of the Securities Exchange Act of 1934~~Monday, asNovember ~~amended~~17, ~~or the Exchange Act~~2025, to ~~and~~provide isa ~~not~~general ~~incorporated~~business byupdate. ~~reference into any of~~ Elite’s ~~filings under~~will ~~the~~respond ~~Securities~~to ~~Act~~various ofstockholder ~~1933,~~questions assubmitted ~~amended,~~prior orto the ~~Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing~~call.

Conference Call Information

Date:	November 17, 2025
Time:	11:30 AM EST
Dial-in numbers:	1-800-346-7359 (domestic)
	1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com
	Financial questions by 7:00 PM EST on Friday, November 14, 2025
Audio Replay:	https://elite.irpass.com/events_presentations

Item 7.01 Regulation FD Disclosure.

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 1214, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025	ELITE PHARMACEUTICALS, INC.
	By:	/s/ Nasrat Hakim
		Nasrat Hakim, President and CEO

Dated: November 14, 2025

ELITE PHARMACEUTICALS, INC.

	By:	/s/ Nasrat Hakim
		Nasrat Hakim, President and CEO

Filing Compare · ELITE PHARMACEUTICALS INC /NV/